Children descending from pregnancies complicated by gestational hypertension (GH), preeclampsia (PE) or fetal growth restriction (FGR) have a lifelong cardiovascular risk. The aim of the study was to verify if pregnancy complications induce postnatal alterations in gene expression of microRNAs associated with cardiovascular/cerebrovascular diseases. Twenty-nine microRNAs were assessed in peripheral blood, compared between groups, and analyzed in relation to both aspects, the current presence of cardiovascular risk factors and cardiovascular complications and the previous occurrence of pregnancy complications with regard to the clinical signs, dates of delivery, and Doppler ultrasound examination. The expression profile of miR-21-5p differed between controls and children with a history of uncomplicated pregnancies with abnormal clinical findings. Abnormal expression profile of multiple microRNAs was found in children affected with GH (miR-1-3p, miR-17-5p, miR-20a-5p, miR-21-5p, miR-23a-3p, miR-26a-5p, miR-29a-3p, miR-103a-3p, miR-125b-5p, miR-126-3p, miR-133a-3p, miR-146a-5p, miR-181a-5p, miR-195-5p, and miR-342-3p), PE (miR-1-3p, miR-20a-5p, miR-20b-5p, miR-103a-3p, miR-133a-3p, miR-342-3p), and FGR (miR-17-5p, miR-126-3p, miR-133a-3p). The index of pulsatility in the ductus venosus showed a strong positive correlation with miR-210-3p gene expression in children exposed to PE and/or FGR. Any of changes in epigenome (up-regulation of miR-1-3p and miR-133a-3p) that were induced by pregnancy complications are long-acting and may predispose children affected with GH, PE, or FGR to later development of cardiovascular/cerebrovascular diseases. Novel epigenetic changes (aberrant expression profile of microRNAs) appeared in a proportion of children that were exposed to GH, PE, or FGR. Screening of particular microRNAs may stratify a highly risky group of children that might benefit from implementation of early primary prevention strategies.

Department of Molecular Biology and Cell Pathology 3rd Faculty of Medicine Charles University 10000 Prague Czech Republic

Institute for the Care of the Mother and Child 3rd Faculty of Medicine Charles University 14700 Prague Czech Republic

Zobrazit více v PubMed

Davis E.F., Lazdam M., Lewandowski A.J., Worton S.A., Kelly B., Kenworthy Y., Adwani S., Wilkinson A.R., McCormick K., Sargent I., et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: A systematic review. Pediatrics. 2012;129:e1552–e1561. doi: 10.1542/peds.2011-3093. PubMed DOI

Alsnes I.V., Vatten L.J., Fraser A., Bjørngaard J.H., Rich-Edwards J., Romundstad P.R., Åsvold B.O. Hypertension in Pregnancy and Offspring Cardiovascular Risk in Young Adulthood: Prospective and Sibling Studies in the HUNT Study (Nord-Trøndelag Health Study) in Norway. Hypertension. 2017;69:591–598. PubMed

Tenhola S., Rahiala E., Martikainen A., Halonen P., Voutilainen R. Blood pressure, serum lipids, fasting insulin, and adrenal hormones in 12-year-old children born with maternal preeclampsia. J. Clin. Endocrinol. Metab. 2003;88:1217–1222. doi: 10.1210/jc.2002-020903. PubMed DOI

Øglaend B., Forman M.R., Romundstad P.R., Nilsen S.T., Vatten L.J. Blood pressure in early adolescence in the offspring of preeclamptic and normotensive pregnancies. J. Hypertens. 2009;27:2051–2054. doi: 10.1097/HJH.0b013e328330052a. PubMed DOI

Fraser A., Nelson S.M., Macdonald-Wallis C., Sattar N., Lawlor D.A. Hypertensive disorders of pregnancy and cardiometabolic health in adolescent offspring. Hypertension. 2013;62:614–620. doi: 10.1161/HYPERTENSIONAHA.113.01513. PubMed DOI PMC

Staley J.R., Bradley J., Silverwood R.J., Howe L.D., Tilling K., Lawlor D.A., Macdonald-Wallis C. Associations of blood pressure in pregnancy with offspring blood pressure trajectories during childhood and adolescence: Findings from a prospective study. J. Am. Heart Assoc. 2015;4:e001422. doi: 10.1161/JAHA.114.001422. PubMed DOI PMC

Lazdam M., de la Horra A., Diesch J., Kenworthy Y., Davis E., Lewandowski A.J., Szmigielski C., Shore A., Mackillop L., Kharbanda R., et al. Unique blood pressure characteristics in mother and offspring after early onset preeclampsia. Hypertension. 2012;60:1338–1345. doi: 10.1161/HYPERTENSIONAHA.112.198366. PubMed DOI

Lim W.Y., Lee Y.S., Yap F.K., Aris I.M., Lek N., Meaney M., Gluckman P.D., Godfrey K.M., Kwek K., Chong Y.S., et al. Maternal Blood Pressure During Pregnancy and Early Childhood Blood Pressures in the Offspring: The GUSTO Birth Cohort Study. Medicine (Baltimore) 2015;94:e1981. doi: 10.1097/MD.0000000000001981. PubMed DOI PMC

Jayet P.Y., Rimoldi S.F., Stuber T., Salmòn C.S., Hutter D., Rexhaj E., Thalmann S., Schwab M., Turini P., Sartori-Cucchia C., et al. Pulmonary and systemic vascular dysfunction in young offspring of mothers with preeclampsia. Circulation. 2010;122:488–494. doi: 10.1161/CIRCULATIONAHA.110.941203. PubMed DOI

Sarvari S.I., Rodriguez-Lopez M., Nuñez-Garcia M., Sitges M., Sepulveda-Martinez A., Camara O., Butakoff C., Gratacos E., Bijnens B., Crispi F. Persistence of Cardiac Remodeling in Preadolescents with Fetal Growth Restriction. Circ. Cardiovasc. Imaging. 2017;10:e005270. doi: 10.1161/CIRCIMAGING.116.005270. PubMed DOI

Yiallourou S.R., Wallace E.M., Whatley C., Odoi A., Hollis S., Weichard A.J., Muthusamy J.S., Varma S., Cameron J., Narayan O., et al. Sleep: A Window Into Autonomic Control in Children Born Preterm and Growth Restricted. Sleep. 2017;40 doi: 10.1093/sleep/zsx048. PubMed DOI

Rostand S.G., Cliver S.P., Goldenberg R.L. Racial disparities in the association of foetal growth retardation to childhood blood pressure. Nephrol. Dial. Transplant. 2005;20:1592–1597. doi: 10.1093/ndt/gfh833. PubMed DOI

Libby G., Murphy D.J., McEwan N.F., Greene S.A., Forsyth J.S., Chien P.W., Morris A.D., DARTS/MEMO Collaboration Pre-eclampsia and the later development of type 2 diabetes in mothers and their children: An intergenerational study from the Walker cohort. Diabetologia. 2007;50:523–530. doi: 10.1007/s00125-006-0558-z. PubMed DOI

Tappia P.S., Gabriel C.A. Role of nutrition in the development of the fetal cardiovascular system. Expert Rev. Cardiovasc. Ther. 2006;4:211–225. doi: 10.1586/14779072.4.2.211. PubMed DOI

Lloyd-Jones D.M., Hong Y., Labarthe D., Mozaffarian D., Appel L.J., Van Horn L., Greenlund K., Daniels S., Nichol G., Tomaselli G.F., et al. Defining and setting national goals for cardiovascular health promotion and disease reduction: The American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation. 2010;121:586–613. doi: 10.1161/CIRCULATIONAHA.109.192703. PubMed DOI

Elmén J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., Hedtjärn M., Hansen J.B., Hansen H.F., Straarup E.M., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008;36:1153–1162. doi: 10.1093/nar/gkm1113. PubMed DOI PMC

Yang K., He Y.S., Wang X.Q., Lu L., Chen Q.J., Liu J., Sun Z., Shen W.F. MiR-146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 2011;585:854–860. doi: 10.1016/j.febslet.2011.02.009. PubMed DOI

Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–984. doi: 10.1038/nature07511. PubMed DOI

Xin M., Small E.M., Sutherland L.B., Qi X., McAnally J., Plato C.F., Richardson J.A., Bassel-Duby R., Olson E.N. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev. 2009;23:2166–2178. doi: 10.1101/gad.1842409. PubMed DOI PMC

Li S., Zhu J., Zhang W., Chen Y., Zhang K., Popescu L.M., Ma X., Lau W.B., Rong R., Yu X., et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation. 2011;124:175–184. doi: 10.1161/CIRCULATIONAHA.110.012237. PubMed DOI

Harris T.A., Yamakuchi M., Ferlito M., Mendell J.T., Lowenstein C.J. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc. Natl. Acad. Sci. USA. 2008;105:1516–1521. doi: 10.1073/pnas.0707493105. PubMed DOI PMC

Wang Y.S., Wang H.Y., Liao Y.C., Tsai P.C., Chen K.C., Cheng H.Y., Lin R.T., Juo S.H. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc. Res. 2012;95:517–526. doi: 10.1093/cvr/cvs223. PubMed DOI

Kong L., Zhu J., Han W., Jiang X., Xu M., Zhao Y., Dong Q., Pang Z., Guan Q., Gao L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011;48:61–69. doi: 10.1007/s00592-010-0226-0. PubMed DOI

Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., Dean D.B., Zhang C. MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation. Circ. Res. 2007;100:1579–1588. doi: 10.1161/CIRCRESAHA.106.141986. PubMed DOI

Raitoharju E., Lyytikäinen L.P., Levula M., Oksala N., Mennander A., Tarkka M., Klopp N., Illig T., Kähönen M., Karhunen P.J., et al. miR-21, miR-210, miR-34a, and miR-146a/b are up-regulated in human atherosclerotic plaques in the Tampere Vascular Study. Atherosclerosis. 2011;219:211–217. doi: 10.1016/j.atherosclerosis.2011.07.020. PubMed DOI

Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K., Mercatanti A., Hammond S., Rainaldi G. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108:3068–3071. doi: 10.1182/blood-2006-01-012369. PubMed DOI

Doebele C., Bonauer A., Fischer A., Scholz A., Reiss Y., Urbich C., Hofmann W.K., Zeiher A.M., Dimmeler S. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood. 2010;115:4944–4950. doi: 10.1182/blood-2010-01-264812. PubMed DOI

Fichtlscherer S., De Rosa S., Fox H., Schwietz T., Fischer A., Liebetrau C., Weber M., Hamm C.W., Röxe T., Müller-Ardogan M., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010;107:677–684. doi: 10.1161/CIRCRESAHA.109.215566. PubMed DOI

van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl. Acad. Sci. USA. 2006;103:18255–18260. doi: 10.1073/pnas.0608791103. PubMed DOI PMC

Ikeda S., Kong S.W., Lu J., Bisping E., Zhang H., Allen P.D., Golub T.R., Pieske B., Pu W.T. Altered microRNA expression in human heart disease. Physiol. Genom. 2007;31:367–373. doi: 10.1152/physiolgenomics.00144.2007. PubMed DOI

D’Alessandra Y., Devanna P., Limana F., Straino S., Di Carlo A., Brambilla P.G., Rubino M., Carena M.C., Spazzafumo L., De Simone M., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart. J. 2010;31:2765–2773. doi: 10.1093/eurheartj/ehq167. PubMed DOI PMC

Beaumont J., López B., Hermida N., Schroen B., San José G., Heymans S., Valencia F., Gómez-Doblas J.J., De Teresa E., Díez J., et al. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-β1 up-regulation. Clin. Sci. (Lond.) 2014;126:497–506. doi: 10.1042/CS20130538. PubMed DOI

Maitrias P., Metzinger-Le Meuth V., Nader J., Reix T., Caus T., Metzinger L. The Involvement of miRNA in Carotid-Related Stroke. Arterioscler. Thromb. Vasc. Biol. 2017;37:1608–1617. doi: 10.1161/ATVBAHA.117.309233. PubMed DOI

Jiang Y., Zhang M., He H., Chen J., Zeng H., Li J., Duan R. MicroRNA/mRNA profiling and regulatory network of intracranial aneurysm. BMC Med. Genom. 2013;6:36. doi: 10.1186/1755-8794-6-36. PubMed DOI PMC

Bienertova-Vasku J., Novak J., Vasku A. MicroRNAs in pulmonary arterial hypertension: Pathogenesis, diagnosis and treatment. J. Am. Soc. Hypertens. 2015;9:221–234. doi: 10.1016/j.jash.2014.12.011. PubMed DOI

Halkein J., Tabruyn S.P., Ricke-Hoch M., Haghikia A., Nguyen N.Q., Scherr M., Castermans K., Malvaux L., Lambert V., Thiry M., et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J. Clin. Investig. 2013;123:2143–2154. doi: 10.1172/JCI64365. PubMed DOI PMC

Lai E.C. Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002;30:363–364. doi: 10.1038/ng865. PubMed DOI

Rosenfeld N., Aharonov R., Meiri E., Rosenwald S., Spector Y., Zepeniuk M., Benjamin H., Shabes N., Tabak S., Levy A., et al. MicroRNAs accurately identify cancer tissue origin. Nat. Biotechnol. 2008;26:462–469. doi: 10.1038/nbt1392. PubMed DOI

Pineles B.L., Romero R., Montenegro D., Tarca A.L., Han Y.M., Kim Y.M., Draghici S., Espinoza J., Kusanovic J.P., Mittal P., et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am. J. Obstet. Gynecol. 2007;196:261.e1–261.e6. doi: 10.1016/j.ajog.2007.01.008. PubMed DOI

Hu Y., Li P., Hao S., Liu L., Zhao J., Hou Y. Differential expression of microRNAs in the placentae of Chinese patients with severe pre-eclampsia. Clin. Chem. Lab. Med. 2009;47:923–929. doi: 10.1515/CCLM.2009.228. PubMed DOI

Maccani M.A., Padbury J.F., Marsit C.J. miR-16 and miR-21 expression in the placenta is associated with fetal growth. PLoS ONE. 2011;6:e21210. doi: 10.1371/journal.pone.0021210. PubMed DOI PMC

Higashijima A., Miura K., Mishima H., Kinoshita A., Jo O., Abe S., Hasegawa Y., Miura S., Yamasaki K., Yoshida A., et al. Characterization of placenta-specific microRNAs in fetal growth restriction pregnancy. Prenat. Diagn. 2013;33:214–222. doi: 10.1002/pd.4045. PubMed DOI

Xu P., Zhao Y., Liu M., Wang Y., Wang H., Li Y.X., Zhu X., Yao Y., Wang H., Qiao J., et al. Variations of microRNAs in human placentas and plasma from preeclamptic pregnancy. Hypertension. 2014;63:1276–1284. doi: 10.1161/HYPERTENSIONAHA.113.02647. PubMed DOI

Hromadnikova I., Kotlabova K., Ivankova K., Vedmetskaya Y., Krofta L. Profiling of cardiovascular and cerebrovascular disease associated microRNA expression in umbilical cord blood in gestational hypertension, preeclampsia and fetal growth restriction. Int. J. Cardiol. 2017;249:402–409. doi: 10.1016/j.ijcard.2017.07.045. PubMed DOI

Hromadnikova I., Kotlabova K., Hympanova L., Krofta L. Cardiovascular and Cerebrovascular Disease Associated microRNAs Are Dysregulated in Placental Tissues Affected with Gestational Hypertension, Preeclampsia and Intrauterine Growth Restriction. PLoS ONE. 2015;10:e0138383. doi: 10.1371/journal.pone.0138383. PubMed DOI PMC

Li J., Dong X., Wang Z., Wu J. MicroRNA-1 in Cardiac Diseases and Cancers. Korean J. Physiol. Pharmacol. 2014;18:359–363. doi: 10.4196/kjpp.2014.18.5.359. PubMed DOI PMC

Li Y.Q., Zhang M.F., Wen H.Y., Hu C.L., Liu R., Wei H.Y., Ai C.M., Wang G., Liao X.X., Li X. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics (Sao Paulo) 2013;68:75–80. doi: 10.6061/clinics/2013(01)OA12. PubMed DOI PMC

Chistiakov D.A., Orekhov A.N., Bobryshev Y.V. Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction) J. Mol. Cell. Cardiol. 2016;94:107–121. doi: 10.1016/j.yjmcc.2016.03.015. PubMed DOI

Tang Y., Zheng J., Sun Y., Wu Z., Liu Z., Huang G. MicroRNA-1 regulates cardiomyocyte apoptosis by targeting Bcl-2. Int. Heart J. 2009;50:377–387. doi: 10.1536/ihj.50.377. PubMed DOI

Terentyev D., Belevych A.E., Terentyeva R., Martin M.M., Malana G.E., Kuhn D.E., Abdellatif M., Feldman D.S., Elton T.S., Györke S. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ. Res. 2009;104:514–521. doi: 10.1161/CIRCRESAHA.108.181651. PubMed DOI PMC

Mogilyansky E., Rigoutsos I. The miR-17/92 cluster: A comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013;20:1603–1614. doi: 10.1038/cdd.2013.125. PubMed DOI PMC

Zhou L., Qi R.Q., Liu M., Xu Y.P., Li G., Weiland M., Kaplan D.H., Mi Q.S. microRNA miR-17-92 cluster is highly expressed in epidermal Langerhans cells but not required for its development. Genes Immun. 2014;15:57–61. doi: 10.1038/gene.2013.61. PubMed DOI

Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., Burchfield J., Fox H., Doebele C., Ohtani K., et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:1710–1713. doi: 10.1126/science.1174381. PubMed DOI

Danielson L.S., Park D.S., Rotllan N., Chamorro-Jorganes A., Guijarro M.V., Fernandez-Hernando C., Fishman G.I., Phoon C.K., Hernando E. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis. FASEB J. 2013;27:1460–1467. doi: 10.1096/fj.12-221994. PubMed DOI PMC

Du W., Pan Z., Chen X., Wang L., Zhang Y., Li S., Liang H., Xu C., Zhang Y., Wu Y., et al. By targeting Stat3 microRNA-17-5p promotes cardiomyocyte apoptosis in response to ischemia followed by reperfusion. Cell. Physiol. Biochem. 2014;34:955–965. doi: 10.1159/000366312. PubMed DOI

Yang S., Fan T., Hu Q., Xu W., Yang J., Xu C., Zhang B., Chen J., Jiang H. Downregulation of microRNA-17-5p improves cardiac function after myocardial infarction via attenuation of apoptosis in endothelial cells. Mol. Genet. Genom. 2018;293:883–894. doi: 10.1007/s00438-018-1426-5. PubMed DOI PMC

Kaucsár T., Révész C., Godó M., Krenács T., Albert M., Szalay C.I., Rosivall L., Benyó Z., Bátkai S., Thum T., et al. Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury. Nucleic Acid Ther. 2013;23:344–354. doi: 10.1089/nat.2013.0438. PubMed DOI PMC

Fang L., Ellims A.H., Moore X.L., White D.A., Taylor A.J., Chin-Dusting J., Dart A.M. Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J. Transl. Med. 2015;13:314. doi: 10.1186/s12967-015-0672-0. PubMed DOI PMC

Wu J., Du K., Lu X. Elevated expressions of serum miR-15a, miR-16, and miR-17-5p are associated with acute ischemic stroke. Int. J. Clin. Exp. Med. 2015;8:21071–21079. PubMed PMC

Chen J., Xu L., Hu Q., Yang S., Zhang B., Jiang H. MiR-17-5p as circulating biomarkers for the severity of coronary atherosclerosis in coronary artery disease. Int. J. Cardiol. 2015;197:123–124. doi: 10.1016/j.ijcard.2015.06.037. PubMed DOI

Mendell J.T. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217–222. doi: 10.1016/j.cell.2008.04.001. PubMed DOI PMC

Brock M., Samillan V.J., Trenkmann M., Schwarzwald C., Ulrich S., Gay R.E., Gassmann M., Ostergaard L., Gay S., Speich R., et al. AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension. Eur. Heart J. 2014;35:3203–3211. doi: 10.1093/eurheartj/ehs060. PubMed DOI

Zhu Y., Tian F., Li H., Zhou Y., Lu J., Ge Q. Profiling maternal plasma microRNA expression in early pregnancy to predict gestational diabetes mellitus. Int. J. Gynaecol. Obstet. 2015;130:49–53. doi: 10.1016/j.ijgo.2015.01.010. PubMed DOI

Dickinson B.A., Semus H.M., Montgomery R.L., Stack C., Latimer P.A., Lewton S.M., Lynch J.M., Hullinger T.G., Seto A.G., et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur. J. Heart Fail. 2013;15:650–659. doi: 10.1093/eurjhf/hft018. PubMed DOI

Rodosthenous R.S., Burris H.H., Sanders A.P., Just A.C., Dereix A.E., Svensson K., Solano M., Téllez-Rojo M.M., Wright R.O., Baccarelli A.A. Second trimester extracellular microRNAs in maternal blood and fetal growth: An exploratory study. Epigenetics. 2017;12:804–810. doi: 10.1080/15592294.2017.1358345. PubMed DOI PMC

Sekar D., Venugopal B., Sekar P., Ramalingam K. Role of microRNA 21 in diabetes and associated/related diseases. Gene. 2016;582:14–18. doi: 10.1016/j.gene.2016.01.039. PubMed DOI

Suárez Y., Fernández-Hernando C., Pober J.S., Sessa W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ. Res. 2007;100:1164–1173. doi: 10.1161/01.RES.0000265065.26744.17. PubMed DOI

Dong S., Ma W., Hao B., Hu F., Yan L., Yan X., Wang Y., Chen Z., Wang Z. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int. J. Clin. Exp. Pathol. 2014;7:565–574. PubMed PMC

Liu Y., Nie H., Zhang K., Ma D., Yang G., Zheng Z., Liu K., Yu B., Zhai C., Yang S. A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes. FEBS Lett. 2014;588:3137–3146. doi: 10.1016/j.febslet.2014.05.067. PubMed DOI

Zhang J., Xing Q., Zhou X., Li J., Li Y., Zhang L., Zhou Q., Tang B. Circulating miRNA-21 is a promising biomarker for heart failure. Mol. Med. Rep. 2017;16:7766–7774. doi: 10.3892/mmr.2017.7575. PubMed DOI

Long B., Gan T.Y., Zhang R.C., Zhang Y.H. miR-23a Regulates Cardiomyocyte Apoptosis by Targeting Manganese Superoxide Dismutase. Mol. Cells. 2017;40:542–549. doi: 10.14348/molcells.2017.0012. PubMed DOI PMC

Wang S., He W., Wang C. MiR-23a Regulates the Vasculogenesis of Coronary Artery Disease by Targeting Epidermal Growth Factor Receptor. Cardiovasc. Ther. 2016;34:199–208. doi: 10.1111/1755-5922.12187. PubMed DOI

Cong X., Li Y., Lu N., Dai Y., Zhang H., Zhao X., Liu Y. Resveratrol attenuates the inflammatory reaction induced by ischemia/reperfusion in the rat heart. Mol. Med. Rep. 2014;9:2528–2532. doi: 10.3892/mmr.2014.2090. PubMed DOI

Gao J., Liu Q.G. The role of miR-26 in tumors and normal tissues. Oncol. Lett. 2011;2:1019–1023. doi: 10.3892/ol.2011.413. PubMed DOI PMC

Zheng L., Lin S., Lv C. MiR-26a-5p regulates cardiac fibroblasts collagen expression by targeting ULK1. Sci. Rep. 2018;8:2104. doi: 10.1038/s41598-018-20561-4. PubMed DOI PMC

Ye Y., Hu Z., Lin Y., Zhang C., Perez-Polo J.R. Downregulation of microRNA-29 by antisense inhibitors and a PPAR-gamma agonist protects against myocardial ischaemia-reperfusion injury. Cardiovasc. Res. 2010;87:535–544. doi: 10.1093/cvr/cvq053. PubMed DOI

Moraes L.N., Fernandez G.J., Vechetti-Júnior I.J., Freire P.P., Souza R.W.A., Villacis R.A.R., Rogatto S.R., Reis P.P., Dal-Pai-Silva M., Carvalho R.F. Integration of miRNA and mRNA expression profiles reveals microRNA-regulated networks during muscle wasting in cardiac cachexia. Sci. Rep. 2017;7:6998. doi: 10.1038/s41598-017-07236-2. PubMed DOI PMC

Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C Caused by Overexpression of microRNA-29a Underlies the Pathogenesis of Atrial Fibrillation. Med. Sci. Monit. 2016;22:2175–2181. doi: 10.12659/MSM.896191. PubMed DOI PMC

Widlansky M.E., Jensen D.M., Wang J., Liu Y., Geurts A.M., Kriegel A.J., Liu P., Ying R., Zhang G., Casati M., et al. miR-29 contributes to normal endothelial function and can restore it in cardiometabolic disorders. EMBO Mol. Med. 2018;10:e8046. doi: 10.15252/emmm.201708046. PubMed DOI PMC

Moncini S., Salvi A., Zuccotti P., Viero G., Quattrone A., Barlati S., De Petro G., Venturin M., Riva P. The role of miR-103 and miR-107 in regulation of CDK5R1 expression and in cellular migration. PLoS ONE. 2011;6:e20038. doi: 10.1371/journal.pone.0020038. PubMed DOI PMC

Huang L., Li L., Chen X., Zhang H., Shi Z. MiR-103a targeting Piezo1 is involved in acute myocardial infarction through regulating endothelium function. Cardiol. J. 2016;23:556–562. doi: 10.5603/CJ.a2016.0056. PubMed DOI

Wang J.X., Zhang X.J., Li Q., Wang K., Wang Y., Jiao J.Q., Feng C., Teng S., Zhou L.Y., Gong Y., et al. MicroRNA-103/107 Regulate Programmed Necrosis and Myocardial Ischemia/Reperfusion Injury Through Targeting FADD. Circ. Res. 2015;117:352–363. doi: 10.1161/CIRCRESAHA.117.305781. PubMed DOI

Deng B., Du J., Hu R., Wang A.P., Wu W.H., Hu C.P., Li Y.J., Li X.H. MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β. Life Sci. 2016;147:117–124. doi: 10.1016/j.lfs.2016.01.043. PubMed DOI

Trajkovski M., Hausser J., Soutschek J., Bhat B., Akin A., Zavolan M., Heim M.H., Stoffel M. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature. 2011;474:649–653. doi: 10.1038/nature10112. PubMed DOI

Shaham L., Binder V., Gefen N., Borkhardt A., Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia. 2012;26:2011–2018. doi: 10.1038/leu.2012.90. PubMed DOI

Tiedt S., Prestel M., Malik R., Schieferdecker N., Duering M., Kautzky V., Stoycheva I., Böck J., Northoff B.H., Klein M., et al. RNA-Seq Identifies Circulating miR-125a-5p, miR-125b-5p, and miR-143-3p as Potential Biomarkers for Acute Ischemic Stroke. Circ. Res. 2017;121:970–980. doi: 10.1161/CIRCRESAHA.117.311572. PubMed DOI

Jia K., Shi P., Han X., Chen T., Tang H., Wang J. Diagnostic value of miR-30d-5p and miR-125b-5p in acute myocardial infarction. Mol. Med. Rep. 2016;14:184–194. doi: 10.3892/mmr.2016.5246. PubMed DOI PMC

Wei M., Gan L., Liu Z., Kong L.H., Chang J.R., Chen L.H., Su X.L. MiR125b-5p protects endothelial cells from apoptosis under oxidative stress. Biomed. Pharmacother. 2017;95:453–460. doi: 10.1016/j.biopha.2017.08.072. PubMed DOI

Bayoumi A.S., Park K.M., Wang Y., Teoh J.P., Aonuma T., Tang Y., Su H., Weintraub N.L., Kim I.M. A carvedilol-responsive microRNA, miR-125b-5p protects the heart from acute myocardial infarction by repressing pro-apoptotic bak1 and klf13 in cardiomyocytes. J. Mol. Cell. Cardiol. 2018;114:72–82. doi: 10.1016/j.yjmcc.2017.11.003. PubMed DOI PMC

Wu X.J., Zhao Z.F., Kang X.J., Wang H.J., Zhao J., Pu X.M. MicroRNA-126-3p suppresses cell proliferation by targeting PIK3R2 in Kaposi’s sarcoma cells. Oncotarget. 2016;7:36614–36621. PubMed PMC

Hsu A., Chen S.J., Chang Y.S., Chen H.C., Chu P.H. Systemic approach to identify serum microRNAs as potential biomarkers for acute myocardial infarction. Biomed. Res. Int. 2014;2014:418628. doi: 10.1155/2014/418628. PubMed DOI PMC

Olivieri F., Spazzafumo L., Bonafè M., Recchioni R., Prattichizzo F., Marcheselli F., Micolucci L., Mensà E., Giuliani A., Santini G., et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications. Oncotarget. 2015;6:35372–35382. doi: 10.18632/oncotarget.6164. PubMed DOI PMC

Jansen F., Stumpf T., Proebsting S., Franklin B.S., Wenzel D., Pfeifer P., Flender A., Schmitz T., Yang X., Fleischmann B.K., et al. Intercellular transfer of miR-126-3p by endothelial microparticles reduces vascular smooth muscle cell proliferation and limits neointima formation by inhibiting LRP6. J. Mol. Cell. Cardiol. 2017;104:43–52. doi: 10.1016/j.yjmcc.2016.12.005. PubMed DOI

Liang H.W., Yang X., Wen D.Y., Gao L., Zhang X.Y., Ye Z.H., Luo J., Li Z.Y., He Y., Pang Y.Y., et al. Utility of miR-133a-3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta-analysis and bioinformatics. Mol. Med. Rep. 2018;17:1469–1484. doi: 10.3892/mmr.2017.8040. PubMed DOI PMC

Wang J., Xu R., Lin F., Zhang S., Zhang G., Hu S., Zheng Z. MicroRNA: Novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology. 2009;113:81–88. doi: 10.1159/000172616. PubMed DOI

van Rooij E., Olson E.N. MicroRNAs: Powerful new regulators of heart disease and provocative therapeutic targets. J. Clin. Investig. 2007;117:2369–2376. doi: 10.1172/JCI33099. PubMed DOI PMC

Kukreja R.C., Yin C., Salloum F.N. MicroRNAs: New players in cardiac injury and protection. Mol. Pharmacol. 2011;80:558–564. doi: 10.1124/mol.111.073528. PubMed DOI PMC

Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., Herias V., van Leeuwen R.E., Schellings M.W., Barenbrug P., et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications for a role of microRNAs in myocardial matrix remodeling. Circ. Res. 2009;104:170–178. doi: 10.1161/CIRCRESAHA.108.182535. PubMed DOI

Liu W., Ling S., Sun W., Liu T., Li Y., Zhong G., Zhao D., Zhang P., Song J., Jin X., et al. Circulating microRNAs correlated with the level of coronary artery calcification in symptomatic patients. Sci. Rep. 2015;5:16099. doi: 10.1038/srep16099. PubMed DOI PMC

Taganov K.D., Boldin M.P., Chang K.J., Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA. 2006;103:12481–12486. doi: 10.1073/pnas.0605298103. PubMed DOI PMC

Paterson M.R., Kriegel A.J. MiR-146a/b: A family with shared seeds and different roots. Physiol. Genom. 2017;49:243–252. doi: 10.1152/physiolgenomics.00133.2016. PubMed DOI PMC

Zhang X., Ye Z.H., Liang H.W., Ren F.H., Li P., Dang Y.W., Chen G. Down-regulation of miR-146a-5p and its potential targets in hepatocellular carcinoma validated by a TCGA- and GEO-based study. FEBS Open Bio. 2017;7:504–521. doi: 10.1002/2211-5463.12198. PubMed DOI PMC

Li S.H., Chen L., Pang X.M., Su S.Y., Zhou X., Chen C.Y., Huang L.G., Li J.P., Liu J.L. Decreased miR-146a expression in acute ischemic stroke directly targets the Fbxl10 mRNA and is involved in modulating apoptosis. Neurochem. Int. 2017;107:156–167. doi: 10.1016/j.neuint.2017.01.011. PubMed DOI

Wang X., Ha T., Liu L., Zou J., Zhang X., Kalbfleisch J., Gao X., Williams D., Li C. Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 2013;97:432–442. doi: 10.1093/cvr/cvs356. PubMed DOI PMC

Quan X., Ji Y., Zhang C., Guo X., Zhang Y., Jia S., Ma W., Fan Y., Wang C. Circulating MiR-146a May be a Potential Biomarker of Coronary Heart Disease in Patients with Subclinical Hypothyroidism. Cell. Physiol. Biochem. 2018;45:226–236. doi: 10.1159/000486769. PubMed DOI

Sun X., Sit A., Feinberg M.W. Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc. Med. 2014;24:105–112. doi: 10.1016/j.tcm.2013.09.002. PubMed DOI PMC

Hulsmans M., Sinnaeve P., Van der Schueren B., Mathieu C., Janssens S., Holvoet P. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J. Clin. Endocrinol. Metab. 2012;97:E1213–E1218. doi: 10.1210/jc.2012-1008. PubMed DOI

Lozano-Bartolomé J., Llauradó G., Portero-Otin M., Altuna-Coy A., Rojo-Martínez G., Vendrell J., Jorba R., Rodríguez-Gallego E., Chacón M.R. Altered Expression of miR-181a-5p and miR-23a-3p Is Associated With Obesity and TNFα-Induced Insulin Resistance. J. Clin. Endocrinol. Metab. 2018;103:1447–1458. doi: 10.1210/jc.2017-01909. PubMed DOI

Du X., Yang Y., Xu C., Peng Z., Zhang M., Lei L., Gao W., Dong Y., Shi Z., Sun X., et al. Upregulation of miR-181a impairs hepatic glucose and lipid homeostasis. Oncotarget. 2017;8:91362–91378. doi: 10.18632/oncotarget.20523. PubMed DOI PMC

Nabih E.S., Andrawes N.G. The Association Between Circulating Levels of miRNA-181a and Pancreatic Beta Cells Dysfunction via SMAD7 in Type 1 Diabetic Children and Adolescents. J. Clin. Lab. Anal. 2016;30:727–731. doi: 10.1002/jcla.21928. PubMed DOI PMC

Wu J., Fan C.L., Ma L.J., Liu T., Wang C., Song J.X., Lv Q.S., Pan H., Zhang C.N., Wang J.J. Distinctive expression signatures of serum microRNAs in ischaemic stroke and transient ischaemic attack patients. Thromb. Haemost. 2017;117:992–1001. PubMed

Zhu J., Yao K., Wang Q., Guo J., Shi H., Ma L., Liu H., Gao W., Zou Y., Ge J. Circulating miR-181a as a Potential Novel Biomarker for Diagnosis of Acute Myocardial Infarction. Cell. Physiol. Biochem. 2016;40:1591–1602. doi: 10.1159/000453209. PubMed DOI

He J.F., Luo Y.M., Wan X.H., Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J. Biochem. Mol. Toxicol. 2011;25:404–408. doi: 10.1002/jbt.20396. PubMed DOI

You X.Y., Huang J.H., Liu B., Liu S.J., Zhong Y., Liu S.M. HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy. Biochemistry. 2014;79:538–544. doi: 10.1134/S0006297914060078. PubMed DOI

Zampetaki A., Attia R., Mayr U., Gomes R.S., Phinikaridou A., Yin X., Langley S.R., Willeit P., Lu R., Fanshawe B., et al. Role of miR-195 in aortic aneurysmal disease. Circ. Res. 2014;115:857–866. doi: 10.1161/CIRCRESAHA.115.304361. PubMed DOI

Du J., Zheng R., Xiao F., Zhang S., He K., Zhang J., Shao Y. Downregulated MicroRNA-195 in the Bicuspid Aortic Valve Promotes Calcification of Valve Interstitial Cells via Targeting SMAD7. Cell. Physiol. Biochem. 2017;44:884–896. doi: 10.1159/000485356. PubMed DOI

Li Y., Yang C., Zhang L., Yang P. MicroRNA-210 induces endothelial cell apoptosis by directly targeting PDK1 in the setting of atherosclerosis. Cell. Mol. Biol. Lett. 2017;22:3. doi: 10.1186/s11658-017-0033-5. PubMed DOI PMC

Zaccagnini G., Maimone B., Di Stefano V., Fasanaro P., Greco S., Perfetti A., Capogrossi M.C., Gaetano C., Martelli F. Hypoxia-induced miR-210 modulates tissue response to acute peripheral ischemia. Antioxid. Redox Signal. 2014;21:1177–1188. doi: 10.1089/ars.2013.5206. PubMed DOI PMC

Diao H., Liu B., Shi Y., Song C., Guo Z., Liu N., Song X., Lu Y., Lin X., Li Z. MicroRNA-210 alleviates oxidative stress-associated cardiomyocyte apoptosis by regulating BNIP3. Biosci. Biotechnol. Biochem. 2017;81:1712–1720. doi: 10.1080/09168451.2017.1343118. PubMed DOI

Li T., Cao H., Zhuang J., Wan J., Guan M., Yu B., Li X., Zhang W. Identification of miR-130a, miR-27b and miR-210 as serum biomarkers for atherosclerosis obliterans. Clin. Chim. Acta. 2011;412:66–70. doi: 10.1016/j.cca.2010.09.029. PubMed DOI

Zhao D.S., Chen Y., Jiang H., Lu J.P., Zhang G., Geng J., Zhang Q., Shen J.H., Zhou X., Zhu W., et al. Serum miR-210 and miR-30a expressions tend to revert to fetal levels in Chinese adult patients with chronic heart failure. Cardiovasc. Pathol. 2013;22:444–450. doi: 10.1016/j.carpath.2013.04.001. PubMed DOI

Lou Y.L., Guo F., Liu F., Gao F.L., Zhang P.Q., Niu X., Guo S.C., Yin J.H., Wang Y., Deng Z.F. miR-210 activates notch signaling pathway in angiogenesis induced by cerebral ischemia. Mol. Cell. Biochem. 2012;370:45–51. doi: 10.1007/s11010-012-1396-6. PubMed DOI

Wang L., Xu L., Xu M., Liu G., Xing J., Sun C., Ding H. Obesity-Associated MiR-342-3p Promotes Adipogenesis of Mesenchymal Stem Cells by Suppressing CtBP2 and Releasing C/EBPα from CtBP2 Binding. Cell. Physiol. Biochem. 2015;35:2285–2298. doi: 10.1159/000374032. PubMed DOI

Collares C.V., Evangelista A.F., Xavier D.J., Rassi D.M., Arns T., Foss-Freitas M.C., Foss M.C., Puthier D., Sakamoto-Hojo E.T., Passos G.A., et al. Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res. Notes. 2013;6:491. doi: 10.1186/1756-0500-6-491. PubMed DOI PMC

Eissa S., Matboli M., Bekhet M.M. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. Biomed. Pharmacother. 2016;83:92–99. doi: 10.1016/j.biopha.2016.06.018. PubMed DOI

Cheng S., Cui Y., Fan L., Mu X., Hua Y. T2DM inhibition of endothelial miR-342-3p facilitates angiogenic dysfunction via repression of FGF11 signaling. Biochem. Biophys. Res. Commun. 2018;503:71–78. doi: 10.1016/j.bbrc.2018.05.179. PubMed DOI

Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010;260:70–74. doi: 10.1016/j.cellimm.2009.10.012. PubMed DOI

Khalyfa A., Kheirandish-Gozal L., Bhattacharjee R., Khalyfa A.A., Gozal D. Circulating microRNAs as Potential Biomarkers of Endothelial Dysfunction in Obese Children. Chest. 2016;149:786–800. doi: 10.1378/chest.15-0799. PubMed DOI PMC

ACOG Practice Bulletin Diagnosis and management of preeclampsia and eclampsia. Obstet. Gynecol. 2002;99:159–167. PubMed

Figueras F., Gratacos E. Stage-based approach to the management of fetal growth restriction. Prenat. Diagn. 2014;34:655–659. doi: 10.1002/pd.4412. PubMed DOI

Baschat A.A. Neurodevelopment following fetal growth restriction and its relationship with antepartum parameters of placental dysfunction. Ultrasound. Obstet. Gynecol. 2011;37:501–514. doi: 10.1002/uog.9008. PubMed DOI

Nardozza L.M., Caetano A.C., Zamarian A.C., Mazzola J.B., Silva C.P., Marçal V.M., Lobo T.F., Peixoto A.B., Araujo Júnior E. Fetal growth restriction: Current knowledge. Arch. Gynecol. Obstet. 2017;295:1061–1077. doi: 10.1007/s00404-017-4341-9. PubMed DOI

Vyas S., Nicolaides K.H., Bower S., Campbell S. Middle cerebral artery flow velocity waveforms in fetal hypoxaemia. Br. J. Obstet. Gynaecol. 1990;97:797–803. doi: 10.1111/j.1471-0528.1990.tb02573.x. PubMed DOI

Cohn H.E., Sacks E.J., Heymann M.A., Rudolph A.M. Cardiovascular responses to hypoxemia and acidemia in fetal lambs. Am. J. Obstet. Gynecol. 1974;120:817–824. doi: 10.1016/0002-9378(74)90587-0. PubMed DOI

National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555–576. doi: 10.1542/peds.114.2.S2.555. PubMed DOI

Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. PubMed DOI

Vandesompele J., de Preter K., Pattyn F., Poppe B., Van Roy N., de Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:research0034. doi: 10.1186/gb-2002-3-7-research0034. PubMed DOI PMC

Shapiro S.S., Wilk M.B. An Analysis of Variance Test for Normality (Complete Samples) Biometrika. 1965;52:591–611. doi: 10.1093/biomet/52.3-4.591. DOI

Postnatal Expression Profile of MicroRNAs Associated with Cardiovascular Diseases in 3- to 11-Year-Old Preterm-Born Children

Association Analysis in Children Born from Normal and Complicated Pregnancies-Cardiovascular Disease Associated microRNAs and the Incidence of Prehypertension/Hypertension, Overweight/Obesity, Valve Problems and Heart Defects

Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk

Diabetes Mellitus and Cardiovascular Risk Assessment in Mothers with a History of Gestational Diabetes Mellitus Based on Postpartal Expression Profile of MicroRNAs Associated with Diabetes Mellitus and Cardiovascular and Cerebrovascular Diseases

Evaluation of Vascular Endothelial Function in Young and Middle-Aged Women with Respect to a History of Pregnancy, Pregnancy-Related Complications, Classical Cardiovascular Risk Factors, and Epigenetics